NICOX news, videos and press releases
For more news please use our advanced search feature.
NICOX - More news...
NICOX - More news...
- Nicox Extends Cash Runway into Q4 2025
- Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
- Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
- Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
- Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected
- Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results
- Nicox and Soleus Sign $16.5 million Royalty and Equity Financing
- Nicox Announces Approval of ZERVIATE in China
- Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board
- Nicox announces attendance at upcoming conferences
- Nicox Provides Second Quarter 2024 Update
- Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director
- Nicox: 2024 Ordinary Shareholder Meeting
- Number of voting rights as of May 31, 2024
- Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024
- Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
- Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting
- Nicox's Shareholder Letter
- Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
- Number of voting rights as of February 29, 2024
- Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
- Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan
- Number of voting rights as of October 31, 2023
- Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones
- Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
- Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million
- Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress
- Nicox: 2023 Ordinary Shareholder Meeting
- Monthly Publication of the Number of Shares Composing the Share Capital and of the Total Number of Voting Rights
